[ad_1]
Minnesota Attorney General Lori Swanson filed a lawsuit against Purdue Pharma's opioid manufacturer, accusing it of violating drug use fraud laws. OxyContin.
Purdue Pharma used representatives, payments to promoters and third parties. front groups to "spread his misleading messages about opioids," said Swanson Monday by announcing the trial in the district court of Hennepin. Minnesota is the 26th state to sue Purdue Pharma this year
Swanson has not disclosed the amount of money Minnesota is seeking – but she said the plan would be to put the money on the books. money earned from trial in the treatment of opioid addiction. Pharma "vigorously" denied the allegations of the lawsuit in a statement released Monday.
"We share the Attorney General's concern about the opioid crisis, but we are disappointed that in the midst of good-faith negotiations with many states, Minnesota has decided to pursue a costly and costly litigation process. prolonged, "said the company release. press release in 1996.
According to the lawsuit, representatives of Purdue Pharma told doctors that OxyContin "did not cause" buzz "or" euphoria "and that She had "less addictive potential". [19659002] "But that could not be further from the truth," said Swanson.
The lawsuit also claims that the company has published or funded publications that minimize the risks of opioid addiction. One of these publications stated that "addiction is a disease. This is not caused by drugs; it is triggered in a vulnerable person by exposure to drugs, most often through abuse.
RELATED: Opioid crisis in Minnesota According to Centers for Disease Control and Prevention, one in five patients who used opioids such as OxyContin for treatment still used them after three years. [19659002] Purdue Pharma marketed OxyContin as a 12-hour pain-relieving medication for doctors, and said patients who did not receive 12-hour pain relief should simply increase their doses, states of Purdue Pharma's research, however, shows that the drug disappears in less than 10 hours in more than 50% of patients.
Purdue Pharma said in a statement Monday that Swanson falsely accused company of providing misleading information Prescribers The company stated that the information provided to prescribers about opioids was "scientific and medical information q The FDA has specifically reviewed and continues to approve. "Purdue Pharma also stated" to believe that it is inappropriate for the state to substitute its judgment "for the judgment. Two weeks ago, Purdue Pharma was put an end to its sales activities with those who prescribe drugs, said Monday the company in its statement. She ended her opioid promotions in February
The company said she "will continue to work with states to bring meaningful solutions to the opioid overdose crisis."
SIMILAR CASE STILL PENDING
This is the second
Swanson and the Minnesota Pharmacy Council sued on May 30 against Insys Therapeutics Inc., accusing the Arizona company of tactics illegal sales "cheeky".
Its Subsys Fentanyl analgesic – which has been approved only by the Federal Food and Drug Administration for treating excruciating pain in cancer patients – has been marketed for other uses and at higher doses than what the FDA had approved, the lawsuit. still waiting. Drug manufacturers have denied allegations that they have misled physicians or patients about the safety of opioids.
In a statement, Insys said that she was taking allegations of "bad acts committed by former employees with the utmost gravity".
FATAL IMPACT OF THE ABUSE
The US Centers for Disease Control and Prevention reported more than 42,000 opioid-related overdose deaths in the United States in 2016, adding that According to the Ministry of Minnesota's Health, Opioid deaths in Minnesota have gone from 395 in 2016 to 401 in 2017.
This means that over the past two years, opioids have been the focus of An overdose epidemic of opioids. "The opioid epidemic knows no boundaries by gender, age, political persuasion or geography," said Swanson. "It can have an impact on anyone."
Source link
